Company Overview of Genzyme Corporation
Genzyme Corporation, a biotechnology company, engages in the discovery and development of products and services primarily in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases, and endocrinology. It offers Cerezyme to treat gaucher disease type I; Fabrazyme to treat fabry disease; Aldurazyme for mucopolysaccharidosis I; Myozyme and Lumizyme for pompe disease; Renagel that reduces phosphorous levels in chronic kidney disease (CKD) patients who are on dialysis; Renvela for use in dialysis patients and patients with earlier stage CKD; Hectorol, a vitamin D2 treatment for secondary hyperparathyroidism in CKD patients; Thyrogen to use in thyroid cancer follow-up; Leuk...
500 Kendall Street
Cambridge, MA 02142
Founded in 1981
Key Executives for Genzyme Corporation
Chief Executive Officer and President
Executive Vice President and President of Manufacturing & Corporate Operations
President of Surgical Products
Executive Vice President of Legal, Executive Vice President of Corporate Development and Secretary
Compensation as of Fiscal Year 2016.
Genzyme Corporation Key Developments
Genzyme Corporation Presents at Leerink Healthcare Summit, Sep-23-2016 11:15 AM
Sep 19 16
Genzyme Corporation Presents at Leerink Healthcare Summit, Sep-23-2016 11:15 AM. Venue: Napa Valley, California, United States. Speakers: Henri Termeer, Former CEO, Chairman & President.
Genzyme Corporation Presents at FT Global Pharmaceutical and Biotechnology Conference 2015, Nov-16-2015 02:35 PM
Sep 29 15
Genzyme Corporation Presents at FT Global Pharmaceutical and Biotechnology Conference 2015, Nov-16-2015 02:35 PM. Venue: Marriott Hotel, Grosvenor Square, London W1K 6JP, United Kingdom. Speakers: David P. Meeker, Chief Executive Officer and President.
Genzyme Corporation Presents at BioPharm America 2015, Sep-15-2015 01:30 PM
Sep 12 15
Genzyme Corporation Presents at BioPharm America 2015, Sep-15-2015 01:30 PM. Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States. Speakers: Henri A. Termeer, Executive Director, Member of Strategic Planning & Capital Allocation Committee and Member of Risk Oversight Committee.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|